Skip to main content
GranumUnited · Oncology

United, Oncology lineage

payer

United

diagnosis

Oncology

generations

10

alive · apoptosed

2 · 18

appeal fitness

62% 98% (+36pp)

Appeal-writer lineage2 alive · 18 apoptosed
0.40.60.81.0gen 0g1g2g3g4g5g6g7g8g9
alive champion experimental apoptosed
What changed G3 — Added NCCN version and FDA label citation requirements. G6 — Added ECOG, therapy line, and precise treatment dates.fitness 0.96 0.98

this mutation: Added ECOG, therapy line, and precise treatment dates.

parent · gen 3
Draft a first-level internal prior-authorization appeal letter for a UnitedHealthcare (UHC) oncology coverage denial. Do not fabricate facts, guidelines, or codes. Ensure clinical specificity by matching the exact administration route (oral vs. IV) to its proper coding. Never use IV infusion CPT codes for oral medications; use the precise oral HCPCS or NDC codes to avoid secondary administrative denials. Explicitly state the appeal is filed within the UHC commercial 65-day timely-filing window. Prove medical necessity by citing exact section numbers from the 'UnitedHealthcare Commercial Medical Drug Policy: Oncology Medication Clinical Coverage'. You must also cite the applicable NCCN guideline, explicitly including its specific version number (e.g., V.1.2024) and category of evidence, along with the exact FDA prescribing information (FDA label) for the requested drug. Map these policy, NCCN, and FDA clauses directly to the patient's medical records. If the denial is not immediately overturned, explicitly request a peer-to-peer (P2P) review with a board-certified oncologist. Keep the letter under 500 words with strict procedural compliance.
this strategy · gen 6
Draft a first-level prior-authorization appeal letter for a UnitedHealthcare (UHC) oncology denial. Never fabricate facts, guidelines, or codes. Ensure clinical specificity by matching the exact administration route to its proper coding (use precise oral HCPCS/NDC codes, never IV CPT codes for oral drugs). Explicitly state the appeal is filed within the UHC commercial 65-day timely-filing window. Prove medical necessity by citing exact section numbers from the 'UnitedHealthcare Commercial Medical Drug Policy: Oncology Medication Clinical Coverage'. Cite the applicable NCCN guideline, including its exact version number (e.g., V.1.2024) and category of evidence, plus the FDA prescribing information. Map these clauses directly to the patient's records. To prevent secondary denials, you must explicitly document the patient's current line of therapy, ECOG performance status, and lack of contraindications. Definitively prove refractory status by detailing specific dates of prior treatments (e.g., radioactive iodine) and dates of subsequent progression imaging. If not immediately overturned, request a peer-to-peer (P2P) review with a board-certified oncologist. Keep under 500 words.
How fitness climbed, generation by generationseed 0.62 → peak 0.98

The population, generation by generation.

Every generation Granum breeds variant appeals, judges them head to head, and lets the weakest die. Pick a generation to see who was bred, who won, who apoptosed, and when a descendant took the crown.

  • bred
  • judged
  • apoptosed
  • crowned
bred
judged
apoptosed
crowned
fitness

Generation 1

fitness 0.90(+0.28)
bred
  • g1m0 bcell_1_generic · Added first-level, 65-day window, and P2P review.
  • g1m1 bcell_1_generic · Structured instructions for procedural compliance and P2P.
judged

4 candidates judged head to head g1m0 won

Clinical specificity is the weakest axis due to a coding error: Retevmo is an oral medication, but the appeal requests CPT 96365 (IV infusion). Correct the CPT code to the appropriate oral HCPCS or NDC code to prevent a secondary administrative denial. Otherwise, the clinical and policy mapping is excellent.

apoptosed
2 strategies lysed: bcell_2_persuasive, bcell_1_generic
crowned
g1m0 took the crown, displacing bcell_1_generic

It reads its own telemetry to improve.

Before breeding each new generation, Granum calls Phoenix get-spans to read back the judge critique its own runs recorded — then the mutator optimizes against the weakness that telemetry surfaces. Champion fitness climbed 0.620.98 (+0.36), each step driven by the generation before it.

Phoenix MCP · get-spans
  1. generation 0 1fitness 0.62 0.90+0.28

    its telemetry flagged

    The weakest axis is Procedural Compliance. The letter omits the specific appeal level, incorrectly cites a 30-day deadline instead of the UHC commercial 65-day window, and fails to request a peer-to-peer review. Fix this by explicitly requesting a first-level internal appeal, confirming submission within the 65-day window, and requesting a P2P review with an oncologist.

    so the next generation

    Structured instructions for procedural compliance and P2P.

  2. generation 1 2fitness 0.90 0.94+0.04

    its telemetry flagged

    Clinical specificity is the weakest axis due to a coding error: Retevmo is an oral medication, but the appeal requests CPT 96365 (IV infusion). Correct the CPT code to the appropriate oral HCPCS or NDC code to prevent a secondary administrative denial. Otherwise, the clinical and policy mapping is excellent.

    so the next generation

    Required exact coding match for administration route.

  3. generation 2 3fitness 0.94 0.98+0.04

    its telemetry flagged

    Policy Citation Quality is the weakest axis. The appeal names the UHC policy and NCCN guidelines, but omits the NCCN version number and the FDA label citation for Retevmo. Add the specific NCCN guideline version (e.g., V.1.2026) and explicitly cite the FDA prescribing information to fully meet the 9-10 anchor.

    so the next generation

    Added NCCN version and FDA label citation requirements.

  4. generation 3 4fitness 0.98 0.98

    its telemetry flagged

    While excellent overall, Clinical Specificity is the weakest axis. The appeal states the patient is radioactive iodine-refractory but omits the dates of prior RAI therapy. Add the specific dates of prior RAI administration and subsequent progression imaging to definitively prove the refractory status required by the FDA label and NCCN guidelines.

    so the next generation

    Mandated dates of prior therapies and imaging.

  5. generation 4 5fitness 0.98 0.98

    its telemetry flagged

    Argumentative Structure is the weakest axis. While the appeal brilliantly dismantles the CPT error and missing RET lab, it misses an opportunity to pre-empt secondary UHC denials by explicitly documenting the patient's ECOG performance status and lack of contraindications to selpercatinib.

    so the next generation

    Added ECOG, contraindications, and prior therapy dates.

  6. generation 5 6fitness 0.98 0.98

    its telemetry flagged

    The appeal perfectly addresses the denial reasons but omits the line of therapy. To achieve a perfect clinical specificity score, explicitly state the patient's current line of therapy and any prior treatments (such as radioactive iodine) to fully contextualize the NCCN and FDA indications for selpercatinib.

    so the next generation

    Added ECOG, therapy line, and precise treatment dates.

  7. generation 6 7fitness 0.98 0.98

    its telemetry flagged

    Argumentative Structure is the weakest axis. The opening sentence states it is an appeal but lacks a direct overturn-request thesis naming the drug and indication. To improve, combine the opening sentence with a clear thesis: 'We request first-level internal reconsideration to overturn the denial of oral selpercatinib for RET-fusion positive thyroid cancer.'

    so the next generation

    Added opening thesis, line of therapy, ECOG status.

  8. generation 7 8fitness 0.98 0.98

    its telemetry flagged

    Clinical specificity is the weakest axis (though still exceptionally strong). While the appeal perfectly addresses the RET fusion and RAI-refractory status, it omits the patient's ECOG performance status. Add the patient's ECOG score to preempt any secondary denial based on general performance status requirements in the UHC oncology policy.

    so the next generation

    Added direct thesis, ECOG status, and therapy line.

  9. generation 8 9fitness 0.98 0.98

    its telemetry flagged

    The weakest axis is Argumentative Structure. While highly organized, the opening thesis states the submission of an appeal but does not explicitly request the overturn of the specific drug denial in the first sentence. Revise the opening to directly request the overturn of the selpercatinib denial.

    so the next generation

    Mandated direct overturn thesis and ECOG score inclusion